SGTA: A Potential Drug Target and Biomarker (G6449)

Target Name: SGTA

NCBI ID: G6449

SGTA

SGTA: A Potential Drug Target and Biomarker

SGTA (Sialic Galectin-Tissue Antigen) is a carbohydrate-based protein that is expressed in various tissues of the body, including the nervous system, endocrine system, and skin. It is a type of glycoprotein, which means it consists of both protein and carbohydrate components. SGTA is also known as GLT-1 (Glycoprotein-Like Transmembrane), and it is found in the cell surface of various cell types.

SGTA is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and various functions make it an attractive target for researchers to study and develop new treatments.

One of the key features of SGTA is its expression in different tissues. It is highly expressed in the brain and nervous system, and it is also found in other tissues, such as the lungs, heart, kidneys, and liver. This makes SGTA an attractive target for studying the effects of drugs on these tissues.

SGTA also has unique functions in the body. It is involved in several physiological processes, including cell signaling, migration, and invasion. It is also involved in the development and maintenance of the immune system.

SGTA has also been shown to play a role in several diseases, including cancer. Studies have shown that SGTA is often overexpressed in cancer cells, and that inhibiting its function may be an effective way to treat cancer.

One of the challenges in studying SGTA is its complex structure. SGTA consists of a long arm with a variable region and a short arm with a constant region. The variable region is responsible for the unique functions of SGTA, and it is the region that is being targeted by many researchers.

In addition, SGTA is also known to be expressed in many different cell types, which can make it difficult to study. To study SGTA, researchers have to use techniques such as mass spectrometry to identify and quantify it in different cell types.

Despite these challenges, SGTA is an attractive drug target and biomarker due to its unique structure and functions. Its potential as a drug target makes it an important area of research for the development of new treatments for a variety of diseases.

In conclusion, SGTA is a carbohydrate-based protein that is expressed in various tissues of the body. It is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and functions make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand SGTA's role in the body and its potential as a drug.

Protein Name: Small Glutamine Rich Tetratricopeptide Repeat Co-chaperone Alpha

Functions: Co-chaperone that binds misfolded and hydrophobic patches-containing client proteins in the cytosol. Mediates their targeting to the endoplasmic reticulum but also regulates their sorting to the proteasome when targeting fails (PubMed:28104892). Functions in tail-anchored/type II transmembrane proteins membrane insertion constituting with ASNA1 and the BAG6 complex a targeting module (PubMed:28104892). Functions upstream of the BAG6 complex and ASNA1, binding more rapidly the transmembrane domain of newly synthesized proteins (PubMed:28104892, PubMed:25535373). It is also involved in the regulation of the endoplasmic reticulum-associated misfolded protein catabolic process via its interaction with BAG6: collaborates with the BAG6 complex to maintain hydrophobic substrates in non-ubiquitinated states (PubMed:23129660, PubMed:25179605). Competes with RNF126 for interaction with BAG6, preventing the ubiquitination of client proteins associated with the BAG6 complex (PubMed:27193484). Binds directly to HSC70 and HSP70 and regulates their ATPase activity (PubMed:18759457)

The "SGTA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGTA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets